In addition, the rapamycin-induced KPNA2 decrease was abolished in the presence of the proteasome inhibitor MG132 (Figure 3B), suggesting that the mTOR pathway modulated the proteasome-mediated KPNA2 degradation in NSCLC cells. Here, MTOR is linked to non-small cell lung carcinoma.